Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
2(14%)
Results Posted
33%(3 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_2
6
43%
Ph phase_4
3
21%
Ph not_applicable
1
7%
Ph phase_3
4
29%

Phase Distribution

0

Early Stage

6

Mid Stage

7

Late Stage

Phase Distribution14 total trials
Phase 2Efficacy & side effects
6(42.9%)
Phase 3Large-scale testing
4(28.6%)
Phase 4Post-market surveillance
3(21.4%)
N/ANon-phased studies
1(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

14

all time

Status Distribution
Active(2)
Completed(9)
Terminated(1)
Other(2)

Detailed Status

Completed9
unknown2
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
2
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 26 (42.9%)
Phase 34 (28.6%)
Phase 43 (21.4%)
N/A1 (7.1%)

Trials by Status

completed964%
unknown214%
terminated17%
recruiting214%

Recent Activity

2 active trials
Showing 5 of 14
completedphase_4

Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease

NCT05493761
recruitingphase_2

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

NCT06016634
terminatedphase_2

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

NCT00019695
unknownphase_2

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

NCT05397938
recruitingphase_3

Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

NCT04704947
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT05493761Phase 4

Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease

Completed
NCT06016634Phase 2

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

Recruiting
NCT00019695Phase 2

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

Terminated
NCT05397938Phase 2

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

Unknown
NCT04704947Phase 3

Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

Recruiting
NCT00354302Phase 3

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial

Completed
NCT02795546Phase 4

Effect of Alendronate With β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-osseous Defects.

Completed
NCT00996801Phase 2

MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

Completed
NCT00004489Not Applicable

Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis

Completed
NCT00004488Phase 2

Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease

Completed
NCT00504166Phase 4

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women

Completed
NCT00122356Phase 3

Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment

Completed
NCT00051558Phase 3

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

Completed
NCT00209469Phase 2

Network Osteoporosis Study

Unknown

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14